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The extended-spectrum-lactamases-producing Escherichia coli has rapidly spread
worldwide. Escherichia coli has been becoming much more resistant to b-lactam
antibiotics and other commonly available antimicrobials. We investigated the prevalence,
resistance, and probable gene type of extended spectrum beta-lactamases (ESBLs)
using minimum inhibitory concentrations (MICs) testing and polymerase chain reaction
(PCR). We have collected 289 single-patient E. coli Isolates based on samples of China
from July 2013 to August 2014. This article explored that the prevalence of ESBL-
producing Isolates showed multi-resistant to antimicrobials such as fluoroquinolones,
trimethoprim, tetracycline and aminoglycosides, and so on. The frequencies of resistance
in Isolates were as follows: Ciprofloxacin, 74%, gentamicin, 69.5%, levofloxacin, 63%,
tobramycin, 39%, and minocycline, 7.9%. According to our results, 197(68.2%) of
the total 289 Isolates were ESBL-producing strains; further, 172 (87.3%) producers
contained genes encoding CTX-M enzymes and 142(72.1%) producers contained genes
encoding TEM enzymes. Most ESBL-producing Escherichia coli has produced more
than one type of b-lactamase. Nucleotide sequence analysis has revealed the diversity
of ESBLs types: CTX-M -15 is in the majority and TEM-135, CTX-M-3, CTX-M-98,
CTX-M-14, CTX-M-142, CTX-M-65, CTX-M-55, CTX-M-27, and CTX-M-123 have been
recovered. The results confirm that ESBL producers which are common in hospital
strains of Escherichia coli are resistant to cephalosporins and other antibiotics in China.
It is important to monitor such strains closely and provide scientific evidence of rational
application of antibiotics to prevent their spread.
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Introduction
The resistance of ESBL-producing Enterobacteriaceae has currently become one of the most
important nosocomial resistance problems around the world and it has been found that there
are much more community-acquired ones (Bradford, 2001; Valverde et al., 2004). Escherichia coli
has been a universal commensal bacterium causing infections in humans and animals and often
leads to urinary tract infections (UTI) and bacteremia for humans (Paterson and Bonomo, 2005).
ESBL-producing Enterobacteriaceae were firstly reported in the middle of 1980s in Germany, since
then a steady increase of these strains have been reported worldwide (Bradford, 2001).
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Recently, researchers have paid much more attention to
extended spectrum beta-lactamases (ESBLs). As well known, the
production of b-lactamase is the most common mechanism of
bacterial resistance to b-lactam antibiotics; with the introduction
of extended-spectrum cephalosporins, ESBLs has spread across
the world (Medeiros, 1997; Yagi et al., 2000; Saladin et al., 2002;
Yong and Toleman, 2009). ESBLs could inactivate oxyimino-b-
lactams like third-generation cephalosporins and aztreonam, but
not hydrolyze the carbapenems, which are highly susceptible to
inhibition by clavulanic acid and tazobactam (Livermore, 1995).
ESBL-producing strains are not only highly resistant to b-lactam
antibiotics but also resistant to aminoglycosides, quinolones, sul-
fonamides, and so on (Ho et al., 2007).
The epidemic situation, resistance and genotype distribution
of ESBL-producing strains have varied with different countries,
regions and even hospitals. ESBL strains have extended all over the
world stage by stage, while detectable rates have shown significant
difference in different hospitals or areas of the same country.
Previous researches have indicated the detectable rate of ESBL-
producing strains from5 to 8%ofEscherichia coli Isolates inKorea,
Japan, Malaysia, and Singapore, from 12 to 24% in Thailand,
Taiwan, Philippines, and Indonesia (Paterson and Bonomo, 2005),
from 62 to 100% in India (Mathai et al., 2009). By contrast, the rate
was almost up to 60% in China (Xiao et al., 2011).
Much more genetic subtypes of ESBLs have been found since
1980s, which has exceeded 200 so far. The vast majority of ESBLs
belong to three types, including TEM, SHV, and CTX-M types
(Bauernfeind et al., 1990; Barthelemy et al., 1992; Bradford, 2001;
Paterson and Bonomo, 2005; Livermore et al., 2007; Cantón
et al., 2012). Previous researches exploring TEM-type has mainly
involved the predominant genotype (particularly, TEM-10, TEM-
12, and TEM-26) in north America (Rasmussen et al., 1993;
Urban et al., 1994); 92% ESBL-positive E. coli Isolates expressed
a CTX-M-type enzyme from 2001 to 2006 and CTX-M-1 being
the predominant group in Sweden (Fang et al., 2008); the CTX-
M-15 enzyme was the most prevalent enzyme in United Kingdom
(Baraniak et al., 2005; Livermore et al., 2007). In China, the CTX-
M b-lactamases was the most prevalent ESBLs, mainly including
CTX-M-3,  9,  14, and  15 (Xiong et al., 2002; Yu et al., 2007;
Liu et al., 2009). In short, there exists tremendous variability in
antimicrobial resistance amongst pathogens in different regions
or in different hospitals located the same regions.
Given few wide-ranging survey researches in Shandong
province, China, we aimed to explore ESBLs epidemiology, resis-
tance and resistant genotypes of 289 E. coli strains Isolated from
three hospitals in that area. In addition, we have collected clinical
data about the patients to carry on further research. The study
helps us reveal their distributions and local constitutions in that
area, thus providing guidance for clinical treatment, and then
contributing to avoiding delay the conditions of patients and
medical resources waste.
Materials and Methods
Bacterial Strains
We have collected 289 clinical Isolates of E. coli from patients
in three typical hospitals of Shandong province in, China, from
July 2013 to August 2014. There exist no replicate strains Isolated
from one patient in our samples. Additional information has
been collected with each Isolate, including isolation date, origin
of the specimen, demographic details. Our experiment has been
approved by Medical Ethics Committee of Shandong University
School of Medicine (Grant No. 201401048).
ESBL Identification and Antimicrobial
Susceptibility Testing
Initially, all Isolates were tested using the Kirby Bauer disk
diffusion method according to the Clinical Laboratory Standards
Institute (2013). E. coli ATCC25922 was used as control
strains. The tested antibiotics included: ampicillin, ampicillin/
sulbactam, amoxicillin/clavulanate, ticarcillin, piperacillin,
piperacillin/tazobactam, cephalothin, cefuroxime, cefoxitin,
ceftriaxone, cefotaxime, ceftazidime, cefepime, meropenem, and
aztreonam (Mast Diagnostics, Merseyside, UK). co-trimoxazole,
gentamicin, nalidixic acid, ciprofloxacin, imipenem, meropenem,
tetracycline, and nitrofurantoin (Oxoid Ltd., Basingstoke, UK).
MIC values were extrapolated by the BIOMIC automated reading
system and software package (Giles Scientific, New York, NY,
USA).
The disk diffusion method was applied to assess ESBL produc-
tion in all the Isolates with cefotaxime (30 ug) and ceftazidime
(30 ug) alone and in combination with clavulanic acid (10 ug) as
recommended by the Clinical and Laboratory Standards Institute
(CLSI).
Nucleic Acid Extractions
DNA had been extracted from the Isolates by using boiling meth-
ods. Each strain was suspended in 500 ul of distilled water at
concentration of MacFarland 0.5 and boiled at 100°C for 10 min.
Then spined it in a centrifuge and kept the supernatant fluid in the
 20°C freezer.
Polymerase Chain Reaction Detection
and Sequencing of ESBLs
To determine the genotype of ESBLs, we performed poly-
merase chain reaction (PCR) amplification with the TEM and
CTX-M. ESBLs Isolates were amplified with primers (Essack
et al., 2001): 50-ATGAGTATTC AACATTTCCGTG-3 and 50-
TTACCAATGCTTAATCAGTGAG-3, which have been designed
to amplify TEM gene (length, 840 bp). Cycling conditions were
as following: initial denaturation at 95°C for 3 min; 35 cycles of
95°C for 1 min, 55°C for 1 min and 72°C for 1 min; and a final
elongation at 72°C for 5 min. We applied CTX-M gene primers:
C1 (50-SCSATGTGCAGYACCAGTAA-3) and C2 (50-CCGCRAT
ATGRTTGGTGGTG-3) to detect CTX-M gene (length, 554 bp).
Cycling conditions were as follows: initial denaturation at 94°C for
3min; 35 cycles of 94°C for 30S, 55°C for 30s and 72°C for 45s; and
a final elongation at 72°C for 5 min. PCR reactions for each strain
were repeated at least three times.
Sequencing of TEM and CTX-M genes
The PCR products were purified with a QIA quick PCR purifi-
cation kit (Qiagen, Hilden, Germany) and sequenced on an ABI
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Prism 377 automated sequencer (Perkin-Elmer, Norwalk, CT,
USA). The primers for sequencing were the amplification primer.
All sequences were confirmed by two independent determina-
tions and analyzed by Basic Local Alignment Search Tool.
Results
Bacterial Strains
In our samples, these strains were Isolated mainly from patients
in urinary surgery ward 110 (38.1%) and ICU 63 (21.8%). The
rest in turn were derived from Respiratory Medicine, 27 (9.3%),
Neurosurgery 22 (7.6%), Thoracic Surgery and General Surgery
21 (7.3%), Oncology 11 (3.8%), Orthopedic Surgery 9 (3.1%),
Cardiovascular Medicine 9 (3.1%), Gastroenterology 8 (2.8%),
Endocrinology 7 (2.4%), Neurology 2 (0.7%). A total of 197 ESBL-
producing Isolates were detected phenotypically using the CLSI
criteria for ESBL screening and disk confirmation test, the detec-
tion rate being 68.2% (197/289) (SeeTable 1).We found thatmuch
more ESBL-producing Isolates exited in urinary surgery ward and
ICU and the detection rate were higher than the other wards.
The cohort of 197 patients had a mean age of 53.8, which ranges
from 20 to 88 (See Table 2). Of all Isolates, 109 (55.3%) patients
were over 60. According to statistical results by age, we concluded
that we should further enhance elderly patients’ management
and treatment dynamics, completes the prevention and treatment
work. The main sources of ESBL- producing E-coil were unire 96
(48.73%, of total ESBL-producing Isolates), wounds 27 (13.71%),
sputa 26 (13.20%), genital secretion 16 (8.12%), hydrothorax and
ascite 15 (7.61%), blood 12 (6.09%), bile 5 (2.54%) (See Table 3).
Antimicrobial Susceptibility
The ESBL-producing Isolates were often multidrug-resistant.
ESBL producers have shown much higher rates of resistance
than those non-ESBL to ciprofloxacin (ESBL versus non-ESBL,
TABLE 1 | Distribution of strains in different wards.
Wards Total ESBLs Detection rate
Urology 110 74 67.27%
Intensive care unit 64 54 84.38%
Respiratory medicine 27 17 62.96%
Neurosurgery 22 13 59.09%
Thoracic surgery and general surgery 21 13 61.90%
Oncology 11 7 63.64%
Cardiovascular medicine 9 3 33.33%
Orthopedic surgery 9 5 55.56%
Endocrinology 8 5 62.50%
Gastroenterology 6 4 66.67%
Neurology 2 1 50.00%
Total 289 197 68.2%
TABLE 2 | Frequency of ESBL Isolates by age.
XXXXXXXXGender
Age 20–40 40–60 60–80 >80 Total
Male 15 24 43 14 96
Female 21 28 40 12 101
Total 36 52 83 26 197
74% versus 30%, P < 0.01), gentamicin (69.5% versus 28.5%,
P < 0.01), co-trimoxazole (75.8% versus 36%, P < 0.01), aztre-
onam (79% versus 20.5%, P< 0.01), and levofloxacin (63% versus
40%, P < 0.01). The great majority of Isolates were susceptible
to Minocycline (ESBL versus non-ESBL, 82% versus 92.1%). All
Isolates were susceptible to amikacin and imipenem ($2 test for
all groups).
Characteristics of the ESBL-producing Isolates
All 197 Isolates with an ESBL phenotype tested positive for
blaCTX-M and blaTEM using the consensus primers. We
found 172 (87.3%) Isolates were positive for blaCTX-M, while
142(72.1%) Isolates were positive for blaTEM and 11 non-TEM-
CTX-M-type Producers. In addition, most Isolates appeared to
produce both TEM and CTX-M enzymes (128). Using nucleotide
sequence analysis we found that the TEM enzymes detected two
types which were TEM-1(138) and TEM-135(4) b-lactamase.
Unlike the TEM enzymes, the CTX-M enzymes with a variety
of types includedCTX-M-3(16), CTX-M-14(77), CTX-M-15(64),
CTX-M-55(9), CTX-M-64(1), CTX-M-65(2) and CTX-M-98(3)
and the genes of CTX-M-14 and CTX-M-15 were in the
majority.
Discussion
In the article, 289 E. coli Isolates were collected from patients from
July 2013 to August 2014; the detection rate of ESBL producers
was 68.2%whichwas significantly higher than previous researches
(Xiao et al., 2011). Therefore, we should pay more attention to
the problem and try to take appropriate prevention and remedial
measures. We found that much more ESBL-producing Isolates
in urinary surgery ward and ICU and the detection rate were
higher than the other wards. Because amajority of patients in ICU
acquired serious diseases lowering their immunity, and involved
heavy use of antibiotics for a long time, both of which con-
tributing to higher detection rates. And for patients in urinary
surgery, higher detection rates were related to their selves char-
acteristics, one of which was mainly urinary tract obstruction in
favors of bacteria propagation, in addition to urethral catheteri-
zation, further increasing opportunities for infection. Besides, we
found most ESBL-producing strains occur in old man or woman,
because the elderly themselves have low immunity. And in the
patients, one patient over 60 repeatedly infected with the ESBL-
producing E. coli. As a long duration of extended-spectrum b-
lactamase-producing Enterobacteriaceae carriage after discharge
TABLE 3 | Distribution of E. coli Isolates by type of specimen.
Specimen type Total ESBLs Non-ESBLs
Unire 126 96 30
Wounds 42 27 15
Sputa 38 26 12
Genital secretion 28 16 12
Hydrothorax and ascite 26 15 11
Blood 20 12 8
Bile 9 5 4
Total 289 197 92
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(Birgand et al., 2013), we concluded that those patients underlying
chronic illnesses which had lowered their immunity were apt to
be infected with ESBL-producing E. coli. Therefore, we should
initiate active interventions and treatments.
The susceptibility test data showed that the ESBL producers
which were resistant to most-lactams and frequently resistant
to the non-b-lactam antibiotics, for example, fluoroquinolones
and aminoglycosides. If patients are infected by ESBL produc-
ers, cefmetazole, or imipenem will be chosen before results of
antibiotic susceptibility test having been done. But if patients
are in a critical condition, we should make choice of car-
bapenems (Paterson, 2000). ESBL producers have shown much
higher rates of resistance than those non-ESBL. Therefore,
we should avoid antibiotics abuse in outpatient clinic and
community hospitals, reducing opportunities for emergence of
ESBLs.
TEM is the main type of b-lactamase, the TEM-1 group being
the most common ones. CTX-M enzymes was a new group of
plasmid-mediated ESBLs which has become the predominant
ESBLs reported in Europe from last decade and has increased dra-
matically in many countries (Bonnet, 2004; Cantón and Coque,
2006; Livermore et al., 2007; Pitout and Laupland, 2008). In dif-
ferent geographic areas, the antibiotic consumption and dissimilar
risk factors might have also contributed to the current epidemiol-
ogy of CTX-M enzymes. Our study found that the CTX-M-14 and
CTX-M-15 were in the majority, Dolejska et al. (2011) and Hiroi
et al. (2012) coincided with that.
Even though we have explored ESBLs epidemiology, resis-
tance and resistant genotypes in three hospitals of Shandong
province, with limitation of small samples, we cannot provide
enough theoretical and practical guidance for clinical treatment.
In the future research, we should base upon more large survey
samples from perspective of increasing patients, hospitals and
regions. On the other hand, because of much more ESBL produc-
ers resistant to carbapenems, to conduct a targeted research, we
will focus on carbapenem-resistant Enterobacteriaceae (Centers
for Disease Control and Prevention, 2013; Asakura et al., 2014).
Given carbapenems being the first-line agent for patients with
ESBL-producing bacteria, the occurrence of resistant organisms
could be related to carbapenems, and thenwewill explorewhether
non-carbapenems plays more efficient role in infections with
ESBL-producing Enterobacteriaceae.
Generally speaking, much more ESBL producers are detected
among E. coli in China. The drug resistance rate of E. coli is high,
with the tendency getting higher. Attaching more importance to
monitor the drug resistance of bacterium and reasonable appli-
cation and control abuse of antibiotics in clinic. Based on local
database, our research have clarified the clinical and epidemiolog-
ical features in Shandong province, which contributes to provide
guidance for identifying appropriate treatment plans according to
patients characteristics, especially for patients underlying chronic
illnesses. We should take measures appropriately, and then con-
tributing to avoiding delay the conditions of patients and medical
resources waste.
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